Press Releases

Date Title and Summary View
Toggle Summary Oxford Immunotec to Participate in Two Investor Conferences
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, is scheduled to participate in the following investor
View HTML
Toggle Summary Oxford Immunotec Reports Third Quarter 2019 Financial Results
Third quarter revenue of $21.2 million, an increase of 32% compared to prior year period Gross margin of 73%, an increase of 150 basis points from the prior year period Positive net income of $0.7 million compared to a net loss of ($3.5) million in prior year period OXFORD, United Kingdom and
View HTML
Toggle Summary Oxford Immunotec Schedules Third Quarter 2019 Earnings Release and Conference Call for November 5, 2019
OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release third quarter 2019 financial results before the open of the market on
View HTML
Toggle Summary Oxford Immunotec to Participate in Two Upcoming Investor Conferences
OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), or the Company, a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt McLaughlin, Chief Financial
View HTML
Toggle Summary Oxford Immunotec Reports Second Quarter 2019 Financial Results
Second quarter revenue of $19.6 million, an increase of 18% compared to prior year period Gross margin of 72.4%, reflecting our shift towards a pure-play kit business Positive net income of $0.6 million compared to a net loss of $6.5 million in prior year period OXFORD, United Kingdom and
View HTML
Toggle Summary Oxford Immunotec Schedules Second Quarter 2019 Earnings Release and Conference Call for August 6, 2019
OXFORD, United Kingdom and MARLBOROUGH, Mass., July 18, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release second quarter 2019 financial results before the open of the market on
View HTML
Toggle Summary Oxford Immunotec Appoints Patrick J. Balthrop, Sr. as Chairman
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 24, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it has appointed Patrick J. Balthrop, Sr. as Chairman of its board of directors.
View HTML
Toggle Summary Oxford Immunotec Welcomes Updated CDC Recommendations for Tuberculosis Screening and Testing of Healthcare Personnel
OXFORD, United Kingdom and MARLBOROUGH, Mass., May 17, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it welcomes the updated Tuberculosis Screening, Testing, and Treatment of U.S.
View HTML
Toggle Summary Oxford Immunotec to Present at the UBS Global Healthcare Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass., May 14, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, will present at the UBS Global Healthcare
View HTML
Toggle Summary Oxford Immunotec Reports First Quarter 2019 Financial Results
First quarter revenue of $14.8 million, an increase of 27% compared to prior year period Gross margins expanded 360bps to 71.4% 86% reduction in net loss to $1.5m OXFORD, United Kingdom and MARLBOROUGH, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the
View HTML